PD 1/PD L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B cell lymphoma having …

Ling Li,Ruifang Sun,Yi Miao,Thai Tran,Lisa Adams,Nathan Roscoe,Bing Xu,Ganiraju C Manyam,Xiaohong Tan,Hongwei Zhang,Min Xiao,Alexandar Tzankov,Carlo Visco,Karen Dybkaer,Govind Bhagat,Wayne Tam,Eric D Hsi,J Han van Krieken,Hua You,Jooryung Huh,Maurilio Ponzoni,Andrés JM Ferreri,Michael B Møller,Miguel A Piris,Mingzhi Zhang,Jane N Winter,L Jeffrey Medeiros,George Z Rassidakis,Christine A Vaupel,Yong Li,Naveen Dakappagari,Zijun Y Xu-Monette,Ken H Young

IF: 8.209

2019-01-01

Modern Pathology

Abstract:Programmed cell death protein 1/programmed cell death protein ligand1 (PD-1/PD-L1) interaction is an important immune checkpoint targeted by anti-PD-1/PD-L1 immunotherapies. However, the observed prognostic significance of PD-1/PD-L1 expression in diffuse large B-cell lymphoma treated with the standard of care has been inconsistent and even contradictory. To clarify the prognostic role of PD-1/PD-L1 expression and interaction in diffuse large B-cell lymphoma, in this study we used 3-marker fluorescent multiplex immunohistochemistry and Automated Quantitative Analysis Technology to assess the CD3+, PD-L1+, and PD-1+ CD3+ expression in diagnostic samples and PD-1/PD-L1 interaction as indicated by presence of PD-1+ CD3+ cells in the vicinity of PD-L1+ cells, analyzed their prognostic effects in 414 patients with de novo diffuse large B-cell lymphoma, and examined whether PD-1/PD-L1 …